

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/601,132	06/20/2003	Anthony P. Shuber	EXT-055	4962
21323 75	90 09/23/2005		EXAMINER	
TESTA, HURWITZ & THIBEAULT, LLP			AEDER, SEAN E	
HIGH STREET 125 HIGH STR			ART UNIT	PAPER NUMBER
BOSTON, MA	02110		1642	

DATE MAILED: 09/23/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/601,132	SHUBER, ANTHONY P.				
Office Action Summary	Examiner	Art Unit				
	Sean E. Aeder, Ph.D.	1642				
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with t	he correspondence address				
A SHORTENED STATUTORY PERIOD FOR RE THE MAILING DATE OF THIS COMMUNICATIO  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a  - If NO period for reply is specified above, the maximum statutory per  - Failure to reply within the set or extended period for reply will, by state of the provided by the Office later than three months after the meanned patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no event, however, may a reply reply within the statutory minimum of thirty (30 riod will apply and will expire SIX (6) MONTHS atute, cause the application to become ABAND	be timely filed  )) days will be considered timely. from the mailing date of this communication.  ONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on _	·		l			
2a) This action is <b>FINAL</b> . 2b) ⊠ T	his action is non-final.		ĺ			
3) Since this application is in condition for allocation closed in accordance with the practice under	•					
Disposition of Claims						
4) ⊠ Claim(s) 1-32 is/are pending in the applicat 4a) Of the above claim(s) is/are witho 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-32 are subject to restriction and/	drawn from consideration.					
Application Papers						
9) The specification is objected to by the Exam	niner.					
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to						
Replacement drawing sheet(s) including the cor						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of:  1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the papplication from the International But * See the attached detailed Office action for a	ents have been received. ents have been received in Apploriority documents have been received in Rule 17.2(a)).	ication No ceived in this National Stage				
Attack manufactures						
Attachment(s)  1) Notice of References Cited (PTO-892)	4) 🔲 Interview Sum	mary (PTO-413)				
2) Notice of Netericles Cited (*10-032)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB Paper No(s)/Mail Date	Paper No(s)/M	hail Date mat Patent Application (PTO-152)				

HI

## **DETAILED ACTION**

## Election/Restrictions

## Species

Claims 5, 6, 8-10, 12, 13, 18, 19, 21-23, 28, 31, and 32 are generic to a plurality of disclosed patentably distinct species comprising the following: loci (claims 6, 19, 28), types of samples (9, 10, 22, 23, 31, 32), types of assays (5, 18, 21), diagnostic exams (8, 21, 31), and cancers (12-13). The products of the above species represent separate and distinct molecules with different structures and functions such that one species could not be interchanged with the other. The methods of the above species represent materially distinct methods which differ at least in objectives, method steps, reagents and/or dosages and/or schedules used, response variables, and criteria for success. The cancers and sample types represent separate and distinct cell types with different morphologies and functions such that one species could not be interchanged with the other. Further, the cancers are distinct diseases which differ at least in etiology, pathology, and mechanisms. As such, each species would require different searches and the consideration of different patentability issues. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the

Application/Control Number: 10/601,132 Page 3

Art Unit: 1642

case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean E. Aeder, Ph.D. whose telephone number is 571-272-8787. The examiner can normally be reached on M-F: 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SEA

GARY B. NICKOL, PH.D. PRIMARY EXAMINER